ArticleJournal for immunotherapy of cancer2023

SAFFRON-103: a phase 1b study of the safety and efficacy of sitravatinib combined with tislelizumab in patients with locally advanced or metastatic non-small cell lung cancer.

Jun Zhao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.